ESMO, the leading European professional organisation for medical oncology has announced that Professor Fabrice André will be the new interim Editor-in-Chief of Annals of Oncology, effective September 14, 2017.
Annals of Oncology is ESMO's flagship scientific journal with an Impact Factor of 11.855, according to the latest Journal Citation Reports. The journal is now ranked 10th in the field, within the top 5% of oncology titles.
Fabrice André is currently Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. His research work in the field of biomarkers and personalised therapies focuses on biomarker discovery, development of targeted agents and implementation of personalised medicine. He is also leading phase I-III trials testing targeted agents in the field of breast cancer and large national trials testing implementation of high throughput technologies in the health care system.
Professor André has published more than 200 peer reviewed papers, including papers in the New England Journal of Medicine, Lancet, Nature Medicine, Science, Lancet Oncology and Journal of Clinical Oncology, either as main or co-author. He is chairman of the biomarker group at UNICANCER (French cooperative group).
Professor André has been a member of the ESMO Educational Committee since 2009; a member of the Annals of Oncology Editorial Board (2010-2013) and Associate Editor since 2014.
He is currently chair of the ESMO Translational Research and Personalised Medicine Working Group.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
